The filing of patents containing DNA sequences has been contentious since it was first attempted two decades or so ago. The issue has often been polarised with companies sometimes seeking to patent broadly and others notably, funders of public research and some key scientists, wishing to make all sequence data fully available to all researchers.
But the climate of free access is under increasing pressure as universities around the world are now setting up offices to encourage and facilitate patent protection of as much of their staff's research as possible to generate potentially lucrative royalty income.
A new report by the Nuffield Council of Bioethics in London is therefore timely in its efforts to try to find a defendable and pragmatic middle ground. It hopes that the report might help pave the way to the patenting of genes in a way that the research community would find acceptable while preserving access to key data for researchers and protecting the investment needed for the development of new medicines based on genetic data. "The aim was to produce a short discussion paper after three or four meetings in a matter of months. That the process took two years and nine meetings testifies to the difficult and complex nature of the issues that were raised," says Ian Kennedy, chairman of the council.
The new report does not say that patenting genes is wrong in principle. What it concludes is that far too many gene patents are being granted by a system that is failing to apply the rules strictly enough. The purpose of patents is to stimulate innovation for the public good and reward people for new inventions. "But many new patents for human DNA are likely to impede innovation and create powerful monopolies capable of charging high prices for tests and drugs based on human genes," says Sandy Thomas, director of the council. "Patents involving human DNA should be granted only in rare cases. They should be the exception rather than the norm."
The most common objection to the patents on gene sequences is that genes occur naturally: they
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New thinking on gene patents
With the number of patent claims including DNA sequence booming, is there a way forward to help resolve disagreements over the many issues involved? One ethical body believes that there is and has produced a new study. Nigel Williams reports. are there to be discovered and not invented. The draft map of the human genome published last year described an estimate of 30,000 to 40,000 genes. But the council found this argument unpersuasive. "Isolated DNA does not occur naturally, and without isolating and cloning a gene, you cannot decipher its sequence. Moreover, the patent system has long recognised useful applications of discoveries as inventions," says Thomas.
Middle ground:
So the report therefore concludes that patent officers are right to conclude that DNA can be considered part of an invention. But the key issue, the committee believes, is the crucial need for a rethink of where to draw the line between a discovery and an invention and to tighten up these criteria. Patenting is a slow process; it can take on average 44 months to get a patent granted in Europe and 25 months in the US. Mechanisms also exist for people to challenge patents but these can take years to carry out. So there is growing pressure on the system to to be fair and accurate in its initial decisions if the system is to maintain support from the research and industrial communities.
The report argues that it is vital in assessing patents involving DNA sequence that it does not follow that all patents on all human genes should be allowed in all circumstances. Inventions must pass three tests to qualify for a patent. They must be useful, novel and not obvious to someone familiar with the field. To look at how these criteria should apply to genes, the committee distinguished between four different uses of DNA sequences: in genetic tests, as research tools, in gene therapy and for producing therapeutic proteins. The same reasoning should apply to patents that are based on claims about gene therapy, the committee says. Once a gene has been linked to a disease, the notion of using it in a treatment is obvious and shouldn't merit the reward of a patent. Patents should be reserved for those who invent safe and effective methods for getting genes into tissues, the report argues.
It is vital in assessing patents involving DNA sequence that it does not follow that all patents on all human genes should be allowed in all circumstances
Also to be discouraged are patents on genes of unknown medical value, the committee believes. "These days, scientists can identify human genes by trawling through databases of human DNA and making 'best guesses' about the biological functions and potential uses of the genes they find there. And past experience suggests that allowing speculation to pass for actual evidence of usefulness is a recipe for hindering research," says Thomas.
A salutary lesson involves the human gene for a receptor known as CCR5. In 1995, a US company called Human Genome Sciences applied to patent the gene for its usefulness in combating viral infections, solely on the basis of its similarity to known DNA sequences. Shortly after, researchers elsewhere discovered that the receptor was HIV's passport into cells. So because of the speculative patent it holds, Human Genome Sciences is entitled to levy royalties from companies that use the receptor to look for potential HIV drugs.
But the committee is keen to highlight what it sees as the benefit of the patent system for DNA sequence work. One type of gene patent is acceptable, the committee feels. Companies and labs should be allowed to own the rights to genes whose protein products are used directly as medicines, such as human insulin or erythropoeitin. The information encoded in such genes is being used to make something of value, and it is in the public interest to create incentives to encourage the costly process of developing a medicine, it believes.
But since genes often carry the instructions for more than one protein, there is a caveat. The rights to a gene should only extend to one protein.
Most of the recommendations are realistic and do not require new laws. They could be achieved by applying the existing criteria for patents more stringently. "Without this, we face the prospect of more attempts to monopolise genes, more high prices for gene tests, and the tying up in legal red tape of ever more human DNA sequences," says Thomas.
Various bodies are now involved in the assessment of the ethical implications of patenting DNA and to consider reform of the current system. The UN, through its Convention on Biological Diversity signed in 1992, places strong emphasis on the fair and equitable sharing of benefits arising from the use of genetic resources. The Council of Europe has since proposed collaborating with the EU, World Intellectual Property Organisation, Food and Agriculture Organisation, World Trade Organisation and UNESCO to discuss a suitable alternative system of protecting intellectual property in relation to biotechnology which would meet the aims of the Convention on Biological Diversity and global interests. The Nuffield Council report may be just one input that suggests how changes to the current patent system might be able to help meet these goals.
